Pathologic Complete Response After Preoperative Ipilimumab and Nivolumab in an HLRCC Patient with Stage III RenalCell Carcinoma. jkcvhl [Internet]. 2026 Jun. 1 [cited 2026 Jun. 4];13(2):21-8. Available from: https://www.jkcvhl.com/index.php/jkcvhl/article/view/455